CoChat
Sign Up
Cited by 22Treatment of Major DepressionElectroconvulsive Therapy StudiesTryptophan and brain disorders

Short-term cognitive effects of repeated-dose esketamine in adolescents with major depressive disorder and suicidal ideation: a randomized controlled trial

Open access
Lan, Xiaofeng, Wang, Chengyu, Zhang, Fan, Liu, Haiyan, Li, Weicheng, Ye, Yanxiang, Hu, Zhibo, Mai, Siming +2 more·2023·Child and Adolescent Psychiatry and Mental Health
DOI 10.1186/s13034-023-00647-2PMC PMC10503003
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: Ketamine and its enantiomer have rapid and robust effects on depressive symptom and suicidal ideation. Little is known about their cognitive effects in adolescents. We aimed to evaluate the short-term effect of esketamine on cognition in adolescents with major depressive disorder (MDD) and suicidal ideation. Method: In this randomized-controlled trial, 51 participants aged 13–18 with MDD and suicidal ideation received three intravenous infusions of either esketamine (0.25 mg/kg) or midazolam (0.02 mg/kg). Four dimensions of the MATRICS Consensus Cognitive Battery (MCCB), including processing speed, working memory, verbal learning and visual learning, were assessed at Days 0, 6 and 12. Results: In the linear mixed model, a significant time main effect (F = 12.803, P < 0.001), drug main effect (F = 6.607, P = 0.013), and interaction effect (F = 3.315, P = 0.041) was found in processing speed. Other dimensions including working memory and verbal learning showed significant time main effect (all P < 0.05), but no significant drug or interaction effect (all P > 0.05). Esketamine group showed improvement in processing speed from baseline to Days 6 and 12, and working memory from baseline to Day 12 (all P < 0.05). The generalized estimation equation showed no significant association between baseline cognition and antidepressant or antisuicidal effect (both P > 0.05). Conclusions: The present study suggested that three-dose subanesthetic esketamine infusions did not harm cognition among adolescents with MDD and suicidal ideation. Instead, esketamine may be associated with improvement in processing speed. Trial registration: This trial was registered in the Chinese Clinical Trials Registry (http://www.chictr.org.cn, ChiCTR2000041232).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13034-023-00647-2

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The MCCB has been widely used to assess cognitive functions in clinical trials and shown stable internal consistency and reliability in Chinese patients with MDD of different ages.

    “Studies have showed that MCCB has been widely used to assess cognitive functions in clinical trials and shown stable internal consistency and reliability in Chinese patients with MDD of different ages.28–32”

    From A Randomized Controlled Study of Efficacy and Cognitive Function Improvement of Vortioxetine and Escitalopram in Patients with Depression in Chinese Han Nationality (2024) · cites this paper as [30]

    The Methods (Clinical symptom and cognitive function measurements; page not specified) say the MCCB has been widely used in affective disorders and describe its use to assess cognition in this trial of adolescents with MDD. The paper calls the Chinese version sensitive to impairment in young patients with MDD, but does not report stable internal consistency or reliability across Chinese patients with MDD of different ages. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 45 · Cited by 22

Research works printed but not linked: 43

  1. [1]Berman RM Cappiello A Anand A Oren DA Heninger GR Charney DS Krystal JH Antidepressant effects of ketamine in depressed patients Biol Psychiatry 2000 47 4 351 354 10686270
  2. [2]Murrough JW Iosifescu DV Chang LC Al Jurdi RK Green CE Perez AM Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial Am J Psychiatry 2013 170 10 1134 1142 23982301 PMC3992936
  3. [3]Canuso CM Singh JB Fedgchin M Alphs L Lane R Lim P Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study Am J Psychiatry 2018 175 7 620 630 29656663
  4. [5]Wilkinson ST Ballard ED Bloch MH Mathew SJ Murrough JW Feder A The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis Am J Psychiatry 2018 175 2 150 158 28969441 PMC5794524
  5. [6]Zheng W Zhou YL Liu WJ Wang CY Zhan YN Li HQ Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression J Psychiatr Res 2018 106 61 68 30278319
  6. [7]Zhan Y Zhang B Zhou Y Zheng W Liu W Wang C A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation J Affect Disord 2019 251 205 212 30927581
  7. [8]Dwyer JB Landeros-Weisenberger A Johnson JA Londono Tobon A Flores JM Nasir M Efficacy of intravenous ketamine in adolescent treatment-resistant depression: a randomized midazolam-controlled trial Am J Psychiatry 2021 178 4 352 362 33653121
  8. [9]Papolos DF Teicher MH Faedda GL Murphy P Mattis S Clinical experience using intranasal ketamine in the treatment of pediatric bipolar disorder/fear of harm phenotype J Affect Disord 2013 147 1–3 431 436 23200737
  9. [10]Cullen KR Amatya P Roback MG Albott CS Westlund Schreiner M Ren Y Intravenous ketamine for adolescents with treatment-resistant depression: an open-label study J Child Adolesc Psychopharmacol 2018 28 7 437 444 30004254 PMC6154760
  10. [11]Dwyer JB Beyer C Wilkinson ST Ostroff RB Qayyum Z Bloch MH Ketamine as a treatment for adolescent depression: a case report J Am Acad Child Adolesc Psychiatry 2017 56 4 352 354 28335880
  11. [12]Weber G Yao J Binns S Namkoong S Case report of subanesthetic intravenous ketamine infusion for the treatment of neuropathic pain and depression with suicidal features in a pediatric patient Case Rep Anesthesiol 2018 2018 9375910 30147962 PMC6083543
  12. [13]Zarrinnegar P Kothari J Cheng K Successful use of ketamine for the treatment of psychotic depression in a teenager J Child Adolesc Psychopharmacol 2019 29 6 472 473 31161948
  13. [14]Morgan CJ Muetzelfeldt L Curran HV Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study Addiction 2010 105 1 121 133 19919593
  14. [15]Liang HJ Lau CG Tang A Chan F Ungvari GS Tang WK Cognitive impairments in poly-drug ketamine users Addict Behav 2013 38 11 2661 2666 23899429
  15. [16]Murrough JW Burdick KE Levitch CF Perez AM Brallier JW Chang LC Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial Neuropsychopharmacology 2015 40 5 1084 1090 25374095 PMC4367458
  16. [17]Chen MH Li CT Lin WC Hong CJ Tu PC Bai YM Cognitive function of patients with treatment-resistant depression after a single low dose of ketamine infusion J Affect Disord 2018 241 1 7 30081380
  17. [18]Zhou Y Zheng W Liu W Wang C Zhan Y Li H Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression J Psychopharmacol 2018 32 10 1118 1126 30260273
  18. [19]Murrough JW Wan LB Iacoviello B Collins KA Solon C Glicksberg B Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response Psychopharmacology 2013 10.1007/s00213-013-3255-x 24022236 PMC3952038 · DOI
  19. [20]Shiroma PR Thuras P Wels J Albott CS Erbes C Tye S Lim KO Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression J Affect Disord 2020 277 470 477 32871534
  20. [21]Shiroma PR Albott CS Johns B Thuras P Wels J Lim KO Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression Int J Neuropsychopharmacol 2014 17 11 1805 1813 24963561
  21. [22]Basso L Bönke L Aust S Gärtner M Heuser-Collier I Otte C Antidepressant and neurocognitive effects of serial ketamine administration versus ECT in depressed patients J Psychiatr Res 2020 123 1 8 31981856
  22. [23]McIntyre RS Rosenblat JD Rodrigues NB Lipsitz O Chen-Li D Lee JG The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: results from the Canadian rapid treatment center of excellence (CRTCE) Psychiatry Res 2021 302 113993 34034067
  23. [24]Zhou Y Wang C Lan X Zheng W Li H Chao Z The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality J Psychiatr Res 2021 144 312 319 34715598
  24. [25]Zaki N Chen LN Lane R Doherty T Drevets WC Morrison RL Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study Neuropsychopharmacology 2023 48 8 1225 1233 37173512 PMC10267177
  25. [27]Crisanti C Enrico P Fiorentini A Delvecchio G Brambilla P Neurocognitive impact of ketamine treatment in major depressive disorder: a review on human and animal studies J Affect Disord 2020 276 1109 1118 32777649
  26. [28]Gill H Gill B Rodrigues NB Lipsitz O Rosenblat JD El-Halabi S The effects of ketamine on cognition in treatment-resistant depression: a systematic review and priority avenues for future research Neurosci Biobehav Rev 2021 120 78 85 33242561
  27. [29]Ke X Ding Y Xu K He H Wang D Deng X The profile of cognitive impairments in chronic ketamine users Psychiatry Res 2018 266 124 131 29864611
  28. [30]Zhang C Xu Y Zhang B Hao W Tang WK Cognitive impairment in chronic ketamine abusers Psychiatry Res 2020 291 113206 32763531
  29. [31]Liu H Lan X Wang C Zhang F Fu L Li W The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial BMC Psychiatry 2022 22 1 744 36451150 PMC9710171
  30. [32]Montgomery SA Asberg M A new depression scale designed to be sensitive to change Br J Psychiatry 1979 134 382 389 444788
  31. [33]Beck AT Kovacs M Weissman A Assessment of suicidal intention: the Scale for Suicide Ideation J Consult Clin Psychol 1979 47 2 343 352 469082
  32. [34]Liang S Xing X Wang M Wei D Tian T Liu J Sha S The MATRICS consensus cognitive battery: psychometric properties of the chinese version in young patients with major depression disorder Front Psychiatry 2021 12 745486 34777049 PMC8580868
  33. [35]Van Rheenen TE Rossell SL An empirical evaluation of the MATRICS consensus cognitive battery in bipolar disorder Bipolar Disord 2014 16 3 318 325 24119238
  34. [36]Mohn C Rund BR Neurocognitive profile in major depressive disorders: relationship to symptom level and subjective memory complaints BMC Psychiatry 2016 16 108 27095362 PMC4837617
  35. [37]Halvorsen M Waterloo K Sundet K Eisemann M Wang CE Verbal learning and memory in depression: a 9-year follow-up study Psychiatry Res 2011 188 3 350 354 21429589
  36. [38]Zhou Y Mannan A Han Y Liu H Guan HL Gao X Efficacy and safety of prophylactic use of ketamine for prevention of postanesthetic shivering: a systematic review and meta analysis BMC Anesthesiol 2019 19 1 245 31888509 PMC6937868
  37. [39]Wang J Pu M Effects of esketamine combined with ultrasound-guided nerve block on cognitive function in children with lower extremity fractures Am J Transl Res 2021 13 7 7976 7982 34377278 PMC8340230
  38. [40]Bredlau AL Harel BT McDermott MP Dworkin RH Korones DN Dolan JG Adams HR Neurocognitive changes after sustained ketamine administration in children with chronic pain J Palliat Care Med 2015 5 2 215 26509104 PMC4618408
  39. [41]Thomases DR Cass DK Tseng KY Periadolescent exposure to the NMDA receptor antagonist MK-801 impairs the functional maturation of local GABAergic circuits in the adult prefrontal cortex J Neurosci 2013 33 1 26 34 23283319 PMC3544161
  40. [42]Majewski-Tiedeken CR Rabin CR Siegel SJ Ketamine exposure in adult mice leads to increased cell death in C3H, DBA2 and FVB inbred mouse strains Drug Alcohol Depend 2008 92 1–3 217 227 17920787 PMC2234578
  41. [43]Tuscher JJ Luine V Frankfurt M Frick KM Estradiol-mediated spine changes in the dorsal hippocampus and medial prefrontal cortex of ovariectomized female mice depend on ERK and mTOR activation in the dorsal hippocampus J Neurosci 2016 36 5 1483 1489 26843632 PMC4737764
  42. [44]Kertz SJ Petersen DR Stevens KT Cognitive and attentional vulnerability to depression in youth: a review Clin Psychol Rev 2019 71 63 77 30732975
  43. [45]Zhou Y, Lan X, Wang C, Zhang F, Liu H, Fu L, Li W, Ye Y, Hu Z, Chao Z, Ning Y. Effect of repeated intravenous esketamine on adolescents with major depressive disorder and suicidal ideation: a randomized active-placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2023. 10.1016/j.jaac.2023.05.031. 37414272 · DOI

Authors
Lan, X., Wang, C., Zhang, F., Liu, H., Li, W., Ye, Y., Hu, Z., Mai, S., Ning, Y., & Zhou, Y.
Affiliations
  • Guangzhou Medical University (CN)
  • Southern Medical University (CN)
Corresponding author
  • Ning, Yuping
  • Zhou, Yanling
ORCID
Venue
Child and Adolescent Psychiatry and Mental Health
Publisher
Springer Science and Business Media LLC
Published
2023-09-14
Volume
17
Issue
1
Pages
108-108
ISSN
1753-2000 (ISSN-L)
DOI
10.1186/s13034-023-00647-2
PMC
PMC10503003
OpenAlex
W4386732609
Cited by
22
References
45
Citations by year
2026: 4 · 2025: 8 · 2024: 10
FWCI
3.43
Type
journal article
Language
en
Open access
Licence
Locations
  • Child and Adolescent Psychiatry and Mental Health (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Guangzhou Traditional Chinese Medicine and Integrated Traditional Chinese and Western Medicine Technology Project (20232A010013)
  • Science and Technology Plan Project of Guangzhou (2023A03J0842)
  • Guangzhou Health Science and Technology Project (20231A010038)
  • Science and Technology Program of Guangzhou Liwan District (202201003)
  • Guangdong Basic and Applied Basic Research Foundation (2022A1515011567)
  • Guangzhou Science and Technology Planning Project (202103000032)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
esketamine, major depressive disorder, suicidal ideation, adolescents, cognitive effects, processing speed, working memory, verbal learning, visual learning, rapid-acting antidepressants, MATRICS Consensus Cognitive Battery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review